• Skip to main content

Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

Uncategorized

Solving a Parkinson’s disease puzzle through protein design: breakthrough will open up a new dimension in drug discovery for Parkinson’s disease

June 11, 2020

https://www.sciencedaily.com/releases/2020/06/200611094114.htm

Solving a Parkinson’s disease puzzle through protein design
Date:
June 11, 2020
Source:
Ecole Polytechnique Fédérale de Lausanne
Summary:
Scientists have developed a computational protein design approach, and used it to obtain the first ever high-resolution structure of an activated dopamine receptor in its natural cell membrane environment. The breakthrough will open up a new dimension in drug discovery for Parkinson’s disease and perhaps other disorders.

Safinamide for Levodopa-induced Dyskinesia (PD-LID)

June 17, 2019

https://clinicaltrials.gov/ct2/show/NCT03987750?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F03%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Safinamide for Levodopa-induced Dyskinesia (PD-LID)

DESCRIPTION:
Conditions:   Dyskinesia, Drug-Induced;   Parkinson Disease
Interventions:   Drug: Safinamide Methanesulfonate 150mg;   Drug: Safinamide Methanesulfonate 100mg;   Drug: Safinamide Methanesulfonate matching placebo
Sponsor:   Zambon SpA
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03987750

FIRST POSTED:
Mon, 17 Jun 2019 12:00:00 EDT

LAST UPDATE POSTED:
06/17/19 07:43AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03987750?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F03%2F2019&lupd_d=14&sort=nwst

Powered by Urgent Research

Copyright © 2025 Urgent Research